Atorvastatin, an HMG-CoA reductase inhibitor and efficient lipid-regulating agent. Part I. Synthesis of ring-labeled [14C]atorvastatin

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 42, Issue 2, 1999, Pages 121-127

  Woo, Peter W K ^a   Hartman, Jon ^a   Huang, Yun ^a   Nanninga, Thomas ^a   Bauman, Kelvin ^a   Butler, Donald E ^a   Rubin, John R ^b   Lee, Helen T ^b   Huang, Che C ^a  

^a PFIZER INC   (United States)

^b Chemistry Department   (United States)

Author keywords

Carbon 14 synthesis; HMG CoA reductase inhibitor; Lipid regulating agents; 14C pyrrole ring labeled atorvastatin (Lipitor )

Indexed keywords

AROMATIC COMPOUNDS; CONDENSATION; KETONES; SALTS;

ATORVASTATIN; CALCIUM SALTS; CARBON 14; CARBON-14 SYNTHESIS; HMG-COA REDUCTASE INHIBITOR; LIPID REGULATING AGENTS; PYRROLE RING; SYNTHESISED; [14C]PYRROLE RING-LABELED ATORVASTATIN (LIPITOR®); [CARBONYL;

ESTERS;

ANTILIPEMIC AGENT; ATORVASTATIN; CALCIUM SALT; CARBON 14; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ARTICLE; CATALYST; DRUG SYNTHESIS; POLYMERIZATION;

EID: 0033064955     PISSN: 03624803     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1344(199902)42:2<121::AID-JLCR173>3.0.CO;2-Z     Document Type: Article

References (15)

1. (a) Fortmann, S. P., and Maron, D.J. - Scientific American Medicine 9, Metabolism: II: March 1998.
2. (b) Grundy, S. M. - Postgrad-Med. 102: 81 (1997).
3. (a) Marais A. D., Firth, J. C., Bateman, M. E., Byrnes P, Martens, C., and Mountney, J. -Arteriosclerosis, Thrombosis, and Vascular Biology 17: 1527 (1997), and references therein.
4. (b) Alaupovic, P., Heinonen, T, Shurzinske, L., and Black, D. M. - Atherosclerosis. 133: 123 (1997).
5. (a) Bertolini, S., Bittolo-Bon, G., Malcolm-Campbell, L., Farnier, M., Langan, J., Mahla, G., Pauciullo, P., Sirtori, C., Egros, F., Fayyad, R., and Nawrocki, J. W. - Atherosclerosis 130: 191 (1997).
6. (b) Dart, A., Jerums, G., Nicholson, G., D'Emden, M., Hamilton-Craig, I., Tallis, G., Best, J., West, M., Sullivan, D., Bracs, P., and Black, D. Am. J. Cardiol. 80: 39 (1997).
7. Kelleck, K. A., Burns, K., McAndrew E., Haberl, E., Hook, N, and Ellis, A.K. - Formulary 32: 352 (1997).
8. Lee, H. T. and Woo, P. W. K. - J. Label. Compds. Radiopharm. Following paper.
9. (a) Brower, P. L., Butler, D. E., Deering, C. F., Le, T. V., Millar, A., Nanninga, T. N., and Roth, B. D. - Tetrahedron Lett. 33: 2279 (1992).
10. (b) Baumann, K.L., Butler, D.E., Deering, C.F., Mennen, K.E., Millar, A., Nanninga, T.N., Palmer, C.W., and Roth, B.D. - ibid. 33: 2283 (1992);
11. Butler, D. E., Deering, C. F., Millar, A., Nanningar, T. N., and Roth, B. D. - U.S. Patent 5,149,837, Sept. 22, 1992).
12. In cold runs, the E- and Z-components were separated by silica gel column chromatography (elution with hexane:dichloromethane:EtOAc/9:1:1). TLC (silica gel, pentane:ether/2:1): E-isomer, Rf 0.52; Z-isomer, Rf 0.31. The configuration of the Z-isomer, crystals from ethyl acetate-cyclohexane, was established by single crystal X-ray crystallography. The Z-isomer is favored thermodynamically and the E-isomer is favored kinetically during synthesis.
13. Sttetter, H. and Kuhlmann, H - Organic Reactions 40: 407 (1991).
14. -1, log ε = 4.33, and is 247 nm in the mobile phase under HPLC conditions. Chemical purity by HPLC is defined as purity by area normalization at a chosen wavelength (e.g., 254 nm for 15, as specified for purity determination of the drug), generally near the absorption maximum with consideration being given to the the absorption characteristics of the impurities. During melting point determination (glass capillary, oil bath), atorvastatin, being a calcium salt, decomposed (shrinking, then expanding, and finally melting) over a wide temperature range of approximately 160 to 240 °C.
15. Hurley, T. R., Colson, C. E., Clipper, S. A., Uhlendorf, S. E., and Reily, M. D. - Tetrahedron 49: 1979 (1993).